Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Takeda Put Actos Sales Ahead of Consumer Safety, Lawyer Says
Bloomberg
Wednesday, September 4, 2013 - 9:05am
tags:
Takeda, Actos, bladder cancer, diabetes
AstraZeneca Reports Onglyza Data
Yahoo/Zacks
Wednesday, September 4, 2013 - 8:57am
tags:
Onglyza, AstraZeneca, diabetes
How Congress Encourages Shortages Of Cancer Drugs
Forbes
Tuesday, September 3, 2013 - 4:21pm
tags:
drug shortages
ArQule to cut liver cancer drug dose on safety concerns
Reuters
Tuesday, September 3, 2013 - 4:20pm
tags:
Arqule, liver cancer, tivantinib
Are Biotech M&A Premiums Already Built In? Valuations Do Matter
Seeking Alpha
Tuesday, September 3, 2013 - 4:19pm
tags:
biotech, M&A, ONYX Pharmaceuticals, Alexion, Biomarin, Incyte, Medivation, Pharmacyclics, Regeneron, Seattle Genetics
Safety Concerns May Prevent FDA Approval Of Ligand's Drug Aprela
Seeking Alpha
Tuesday, September 3, 2013 - 4:17pm
tags:
FDA, Ligand, Aprela, menopause, post-menopausal osteoporosis
Targeting An Untapped Female Sexual Dysfunction Drug Market
Seeking Alpha
Tuesday, September 3, 2013 - 11:23am
tags:
female sexual dysfunction, Osphena, Shionogi, flibanserin, Sprout Pharmaceuticals, bremelanotide, Palatin, Femprox, Apricus Biosciences
Coherus inks $246M Baxter deal to develop Enbrel biosimilar
Fierce Biotech
Tuesday, September 3, 2013 - 11:19am
tags:
Coherus Biosciences, Baxter International, Enbrel, biosimilars, Amgen
Philips, J&J land Defense Dept. contracts worth up to $73M
Mass Device
Tuesday, September 3, 2013 - 11:15am
tags:
devices, defense contracts, government contracts, Philips, JNJ
Chinese Police Say Glaxo Practices Come From Unit: Xinhua
Bloomberg
Tuesday, September 3, 2013 - 11:08am
tags:
China, GSK
Is 'No Worse Than Placebo' Good Enough For New Diabetes Drugs?
Forbes
Tuesday, September 3, 2013 - 11:07am
tags:
diabetes, saxagliptin, alogliptin, AstraZeneca, Bristol-Myers Squibb, Takeda
3 Great Reasons Why GlaxoSmithKline plc Is Set To Take Off
Motley Fool
Tuesday, September 3, 2013 - 11:06am
tags:
GSK, M&A, dividends
ImClone’s Waksal Back in Biotech With Plans for Spinouts
Bloomberg
Tuesday, September 3, 2013 - 10:45am
tags:
ImClone, Sam Waksal, biotech, Kadmon
Simultaneous Applications Submitted to EMA and FDA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
Reuters
Tuesday, September 3, 2013 - 10:43am
tags:
EMA, FDA, siltuximab, multicentric Castleman disease
Esperion's drug lowers blood fat in mid-stage study
Reuters
Tuesday, September 3, 2013 - 10:40am
tags:
Esperion Therapeutics, ETC-1002
Amgen, Cytokinetics Report Mixed Results For Heart Failure Drug
TheStreet.com
Tuesday, September 3, 2013 - 10:39am
tags:
Amgen, Cytokinetics, heart failure, Omecamtiv Mecarbil
Can Pharma Hide Side Effects Of Marketed Drugs In The U.S.?
Forbes
Tuesday, September 3, 2013 - 10:38am
tags:
side effects, adverse events
Study finds patients often stop using new AstraZeneca heart drug
Reuters
Tuesday, September 3, 2013 - 10:31am
tags:
Brilinta, AstraZeneca
New Vivus CEO resigns over health issues
Reuters
Tuesday, September 3, 2013 - 10:26am
tags:
Pharma CEOs, Vivus, Anthony Zook, Seth Fischer
Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published
Yahoo
Tuesday, September 3, 2013 - 10:25am
tags:
The Medicines Copmany, Cangrelor

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.